These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24572913)

  • 1. Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study.
    Sakamoto T; Kudoh T; Sakamoto K; Matsui K; Ogawa H
    Hypertens Res; 2014 Jun; 37(6):513-8. PubMed ID: 24572913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
    Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
    Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
    Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does angiotensin receptor blockade ameliorate the prothrombotic tendency in hypertensive patients with atrial fibrillation? Breaking the vicious cycle.
    Takeshita K; Murohara T
    Hypertens Res; 2014 Jun; 37(6):490-1. PubMed ID: 24621475
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
    Sato Y; Fujii S; Imagawa S; Ohmura K; Ohmura Y; Andoh Y; Dong J; Ishimori N; Furumoto T; Tsutsui H
    J Atheroscler Thromb; 2007 Feb; 14(1):31-5. PubMed ID: 17332690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet aggregability by losartan in essential hypertension.
    Levy PJ; Yunis C; Owen J; Brosnihan KB; Smith R; Ferrario CM
    Am J Cardiol; 2000 Dec; 86(11):1188-92. PubMed ID: 11090789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.
    Yamada K; Hirayama T; Hasegawa Y
    J Stroke Cerebrovasc Dis; 2007; 16(5):225-31. PubMed ID: 17845921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
    Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
    J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
    Nattel S
    Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):332-3. PubMed ID: 16265553
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo effect of losartan on platelet aggregation in patients with hypertension.
    Akdemir R; Ozhan H; Yazici M; Gunduz H; Duran S; Gurel C; Ozdas S; Uyan C; Basar I; Ulutin T
    Heart Vessels; 2004 Jul; 19(4):167-71. PubMed ID: 15278389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
    Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
    Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
    Ishikawa A; Ohta N; Ozono S; Kawabe K; Kitamura T
    Transplant Proc; 2005 Mar; 37(2):994-6. PubMed ID: 15848601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.